Inauguration of Sinogen Guangzhou Research and Development Center.

Guangzhou Sinogen Pharmacetutial Co.,Ltd. is a biopharmaceutical company committed to the development and production of innovative biological anti-tumor drugs to meet the global demand for the treatment of a broad malignant tumors.

On December 1, 2022, the Inauguration ceremony of Guangzhou R&D Center of Sinogen Pharmaceutical was held, and R&D center  will be operational officially .

Sinogen Pharmacetutial Guangzhou R&D Center is located in Guangzhou LEDY Life and Health City, Huangpu District, with a total area of nearly 1000m2. R&D Center has complete R&D facilities with Cell-culture lab, Microbiology lab, PCR lab, Pharmacy lab, Animal surgery lab and Physical&Chemical lab. R&D Center will execute development of new drug, exploration on drug mechanism, evaluation of Pharmacy and efficacy. The opening of the R&D center will further promote the development of Sinogen's technology platform for innovative anti-tumor drugs and the development of product pipelines.

Brief Introduction to main products under research in R&D Center
SGN1(SalMet-Vec^®)—the world's first (first in class) genetic engineering biological drug based on bacteria targeting the regulation of tumor amino acid metabolism, is undergoing Phase Ⅰ/Ⅱa clinical trials of intravenous and intratumoral administration for broad-spectrum solid tumors in the United States and Taiwan, China.
SGN2(GenMet-VecTM) is a new oncolytic virus that uses viral vector to carry methionine enzyme. SGN2 has dual anti-tumor mechanisms of immunity and metabolism.
In preclinical studies, SGN2 can inhibit the proliferation of glioma cells in a dose-dependent manner. SGN2 will focus on the treatment of glioblastoma (GBM) and brain metastases.